Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D

Journal of the American Society of Nephrology

Volumn 17, Issue 5, 2006, Pages 1305-1315

  Liu, Shiguang ^a   Tang, Wen ^a   Zhou, Jianping ^a   Stubbs, Jason R ^a   Luo, Qiang ^a   Pi, Min ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VITAMIN D RESISTANT RICKETS; VITAMIN D RESPONSIVE ELEMENT;

EID: 33646367420     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005111185     Document Type: Article

References (46)

1. The ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000
2. Yamashita T, Yoshioka M, Itoh N: Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494-498, 2000
3. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N: Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277: 28265-28270, 2002
4. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
5. Yan X, Yokote H, Jing X, Yao L, Sawada T, Zhang Y, Liang S, Sakaguchi K: Fibroblast growth factor 23 reduces expression of type IIa Na/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 10: 489-502, 2005
6. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
7. Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003
8. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002
9. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683-692, 2003
10. Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004
11. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14: 385-390, 2005
12. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE: A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90: 2424-2427, 2005
13. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004
14. Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E, Furutani J, Ito M, Kuwahata M, Saito H, Fukushima N, Kato S, Kanayama HO, Miyamoto KI: Role of vitamin D receptor on FGF23 action in phosphate metabolism. Biochem J 390: 325-331, 2005
15. Lobaugh B, Drezner MK: Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse. J Clin Invest 71: 400-403, 1983
16. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2003
17. Quarles LD: Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112: 642-646, 2003
18. Xue Y, Karaplis AC, Hendy GN, Goltzman D, Miao D: Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet 14: 1515-1528, 2005
19. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K: A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75: 879-885, 1992
20. Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G: Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406: 199-203, 2000
21. Hruska KA, Rifas L, Cheng SL, Gupta A, Halstead L, Avioli L: X-linked hypophosphatemic rickets and the murine Hyp homologue. Am J Physiol 268: F357-F362, 1995
22. Tu Q, Pi M, Karsenty G, Simpson L, Liu S, Quarles LD: Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 111: 1029-1037, 2003
23. Liu S, Guo R, Tu Q, Quarles LD: Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277: 3686-3697, 2002
24. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD: Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005
25. Sandelin A, Wasserman WW: Prediction of nuclear hormone receptor response elements. Mol Endocrinol 19: 595-606, 2005
26. Pi M, Spurney RF, Tu Q, Hinson T, Quarles LD: Calcium-sensing receptor activation of rho involves filamin and rho-guanine nucleotide exchange factor. Endocrinology 143: 3830-3838, 2002
27. Jurutka PW, Hsieh JC, Remus LS, Whitfield GK, Thompson PD, Haussler CA, Blanco JC, Ozato K, Haussler MR: Mutations in the 1,25-dihydroxyvitamin D3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription factor IIB, in vitro. J Biol Chem 272: 14592-14599, 1997
28. Liu S, Guo R, Quarles LD: Cloning and characterization of the proximal murine Phex promoter. Endocrinology 142: 3987-3995, 2001
29. Quarles LD, Hartle JE 2nd, Siddhanti SR, Guo R, Hinson TK: A distinct cation-sensing mechanism in MC3T3-E1 osteoblasts functionally related to the calcium receptor. J Bone Miner Res 12: 393-402, 1997
30. Ecarot B, Desbarats M: 1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 140: 1192-1199, 1999
31. Hines ER, Kolek OI, Jones MD, Serey SH, Sirjani NB, Kiela PR, Jurutka PW, Haussler MR, Collins JF, Ghishan FK: 1,25-Dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem 279: 46406-46414, 2004
32. Guo R, Liu S, Spurney RF, Quarles LD: Analysis of recombinant Phex: An endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281: E837-E847, 2001
33. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981, 2001
34. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE: Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36: 971-977, 2005
35. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N: Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005
36. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI: Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288: E1101-E1109, 2005
37. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M: Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101: c94-c99, 2005
38. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
39. Kolek OI, Hines ER, Jones MD, Lesueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK: 1alpha,25-Dihydroxyvitamin D3 up-regulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005
40. Liu S, Quarles LD: FGF23: The counter regulatory phosphaturic hormone for vitamin D-mediated hyperphosphatemia. J Bone Minner Res 19: S251, 2004
41. Gloor HJ, Bonjour JP, Caverzasio J, Fleisch H: Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3. J Clin Invest 63: 371-377, 1979
42. Sutton AL, MacDonald PN: Vitamin D: More than a "bone-a-fide" hormone. Mol Endocrinol 17: 777-791, 2003
43. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005
44. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT: FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89: 4489-4492, 2004
45. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
46. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA: Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005